Capricor Therapeutics (CAPR) Misses Q1 EPS by 8c

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.31), $0.08 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $4.91 million versus the consensus estimate of $7.05 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• flyExclusive names Brian P. Reid as chief commercial officer
• This S&P 500 sector offers the best hedge against rising oil prices